Engineering targeted proteases to control cell signaling in cancer
Engineering protein-specific proteases: targeting signaling proteins
['FUNDING_R01'] · UNIV OF MARYLAND, COLLEGE PARK · NIH-10814960
This study is working on creating special proteins that can help control certain signals in cancer cells, especially those related to the RAS family, to better understand and potentially treat cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF MARYLAND, COLLEGE PARK (nih funded) |
| Locations | 1 site (COLLEGE PARK, UNITED STATES) |
| Trial ID | NIH-10814960 on ClinicalTrials.gov |
What this research studies
This research focuses on developing specialized proteases that can precisely target and control signaling proteins involved in cancer, particularly the RAS family of proteins. The approach involves identifying dynamic regions within these proteins and engineering proteases that can activate or inhibit their function in human cell cultures. By utilizing advanced techniques such as protein engineering, enzymology, and cell biology, the researchers aim to create tools that can modulate cancer signaling pathways effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer or those with mutations in RAS proteins.
Not a fit: Patients with cancers unrelated to RAS signaling or those who do not have active RAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that specifically target cancer signaling pathways, potentially improving treatment outcomes for patients with bladder cancer and other RAS-related cancers.
How similar studies have performed: Other research has shown promising results in targeting RAS signaling pathways, indicating that this approach has potential for success.
Where this research is happening
COLLEGE PARK, UNITED STATES
- UNIV OF MARYLAND, COLLEGE PARK — COLLEGE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ORBAN, JOHN — UNIV OF MARYLAND, COLLEGE PARK
- Study coordinator: ORBAN, JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer, Cancer Model, Cancer cell line, CancerModel